Peripheral Neuropathy Trial, Recruiting (NCT06133712)

Peripheral Neuropathy Trial, Recruiting NCT06133712 Sponsor: Tanta University Condition: Peripheral Neuropathy

Printed from Voxsanity (voxsanity.com.au) — NCT06133712 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Neuropathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 20 and 60 years old.
You are male or female.
An ultrasound scan has shown you have mild-to-moderate carpal tunnel syndrome (a condition where a nerve in your wrist is compressed, causing pain and numbness).
You have had numbness and pain in the thumb, index, middle, or ring finger area for at least 3 months.
A nerve conduction test (which measures how well your nerves send signals) has confirmed carpal tunnel syndrome according to recognized medical guidelines.
Your wrist ultrasound shows the affected nerve is a certain size that indicates mild-to-moderate carpal tunnel syndrome (confirm with trial site).

Who may not be able to join:

You do not wish to take part.
Your carpal tunnel syndrome is classed as severe, which would normally require surgery.
Your symptoms have already improved with medication.
You have previously had surgery or injections to treat carpal tunnel syndrome.
You are pregnant.
You have other nerve or shoulder conditions affecting your arm, such as problems with the nerve network in your shoulder, a pinched nerve in your neck, or other nerve damage in your upper limb.
You have a serious heart or blood vessel condition.
Your body mass index (BMI) is over 35 (considered severely obese).
You have a skin infection at the area where the injection would be given.
You have a condition that affects your blood's ability to clot properly.
You have an underactive thyroid, poorly controlled diabetes, rheumatoid arthritis, or a condition called G6PD deficiency (a blood enzyme disorder).
You have a known allergy to ozone or dexmedetomidine (the substances used in this trial).
You have advanced kidney or liver disease.
You have a history of inflammatory joint conditions, connective tissue disorders, burns, scarring that limits movement, or a previous wrist injury.
You are unwilling to complete pain questionnaires and nerve conduction tests before and after the injection.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 13 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: MAHMOUD ELGEBALY, MD, Tanta faculty of medicine

Phone: 00201092415231

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06133712

Sponsor: Tanta University

Phase: Not Applicable

Status: Recruiting

Condition: Peripheral Neuropathy

Trial contact: 00201092415231

More information: https://clinicaltrials.gov/study/NCT06133712

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 20 and 60 years old.
You are male or female.
An ultrasound scan has shown you have mild-to-moderate carpal tunnel syndrome (a condition where a nerve in your wrist is compressed, causing pain and numbness).
You have had numbness and pain in the thumb, index, middle, or ring finger area for at least 3 months.
A nerve conduction test (which measures how well your nerves send signals) has confirmed carpal tunnel syndrome according to recognized medical guidelines.
Your wrist ultrasound shows the affected nerve is a certain size that indicates mild-to-moderate carpal tunnel syndrome (confirm with trial site).

Who may not be able to join:

You do not wish to take part.
Your carpal tunnel syndrome is classed as severe, which would normally require surgery.
Your symptoms have already improved with medication.
You have previously had surgery or injections to treat carpal tunnel syndrome.
You are pregnant.
You have other nerve or shoulder conditions affecting your arm, such as problems with the nerve network in your shoulder, a pinched nerve in your neck, or other nerve damage in your upper limb.
You have a serious heart or blood vessel condition.
Your body mass index (BMI) is over 35 (considered severely obese).
You have a skin infection at the area where the injection would be given.
You have a condition that affects your blood's ability to clot properly.
You have an underactive thyroid, poorly controlled diabetes, rheumatoid arthritis, or a condition called G6PD deficiency (a blood enzyme disorder).
You have a known allergy to ozone or dexmedetomidine (the substances used in this trial).
You have advanced kidney or liver disease.
You have a history of inflammatory joint conditions, connective tissue disorders, burns, scarring that limits movement, or a previous wrist injury.
You are unwilling to complete pain questionnaires and nerve conduction tests before and after the injection.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 13 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Tanta University

Registry

ClinicalTrials.gov

Start date

1 November 2023

Est. completion

1 December 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

The analgesic efficacy and functional status improvement of Dexmedetomidine, Ozone and Dexamethasone regional injection in carpal tunnel syndrome

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov